Browse > Article
http://dx.doi.org/10.3904/kjim.2013.28.2.174

Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-${\alpha}$ inhibitor  

Chung, Keun Bum (Divisions of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine)
Lee, Eun Young (Divisions of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine)
Im, Jong Pil (Division of Gastroenterology and Hepatology, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
Han, Sung Koo (Divisions of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine)
Yim, Jae-Joon (Divisions of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.28, no.2, 2013 , pp. 174-179 More about this Journal
Abstract
Background/Aims: Individuals being treated with tumor necrosis factor (TNF)-${\alpha}$ inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-${\alpha}$ inhibitors. Methods: Patients with TB detected within 12 months of the initiation of TNF-${\alpha}$ inhibitor treatment were included, if seen from January 1, 2000 to August 31, 2011. We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment. Results: We indentified seven cases of TB in 457 patients treated with TNF-${\alpha}$ inhibitors during the study period. TB developed a median of 123 days (range, 48 to 331) after the first dose of TNF-${\alpha}$ inhibitor. Pulmonary TB, including TB pleuritis, was diagnosed in three patients and extrapulmonary TB in four. Favorable treatment outcomes were achieved in six of seven patients. Conclusions: Among the TNF-${\alpha}$ inhibitor users who contracted TB, extrapulmonary sites were common and the treatment response was satisfactory.
Keywords
Tumor necrosis factor-alpha; Tuberculosis; Mycobacterium;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inf liximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098-1104.   DOI
2 Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-1299.   DOI
3 Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant 2012;12:2288-2300.   DOI
4 WHO global tuberculosis control report 2010: summary. Cent Eur J Public Health 2010;18:237.   DOI
5 Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 2007;12:22-25.   DOI
6 Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377.   DOI
7 Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.   DOI
8 Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.   DOI
9 Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun 1999;67:3980-3988.
10 Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.   DOI
11 Ersan S, Celik A, Atila K, et al. Tuberculosis in renal transplant recipients. Ren Fail 2011;33:753-757.   DOI
12 Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002;61:251-253.   DOI
13 Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.   DOI
14 Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol 2011;7:329-340.   DOI
15 Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012;39:807-819.   DOI
16 Joint Committee for the Development of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention, 2011.
17 Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728-6734.   DOI
18 Bean AG, Roach DR, Briscoe H, et al. Structural def iciencies in granuloma formation in TNF genetargeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-3511.
19 Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.   DOI
20 Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-1992.   DOI
21 Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376.   DOI
22 Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-3022.   DOI
23 Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-2127.   DOI
24 Singh JA, Wells GA, Christensen R, et al. Adverse ef fects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794.
25 Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-1255.   DOI
26 Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of inf liximab therapy. Arthritis Rheum 2004;50:372-379.   DOI
27 Korean National Tuberculosis Association. Trend of case notification rate per 100,000 by year, 2004-2011 [Internet]. Seoul (KR): Korean National Tuberculosis Association, c2011 [cited 2013 Feb 1]. Available from: http://www.knta.or.kr.